Which Prostate Cancers Really Need Treatment? -- MIAMI, July 9, 2013 /PRNewswire-iReach/ -- MIAMI, July 9, 2013 /PRNewswire-iReach/ -- Urologyweb.com, a leading website from Dr. Bert Vorstman, has recently posted a new article outlining which prostate cancers really need treatment. Most prostate cancers diagnosed are classed as the low or favorable-risk Gleason 6 (3+3) prostate cancer and the majority of these cancers behave like insignificant pseudo cancers, do not progress and do not need any treatment whether through focal therapy or whole gland treatment. "These cancers should simply be monitored through active surveillance," said Dr Vorstman, a Coral Springs Florida urologistwith over 30 years of experience in managing localized prostate cancer. In addition, Dr Vorstman warned that, "For many men, their road to debilitation and zero benefits began with the highly unreliable PSA prostate cancer screening blood test followed by the risky and painful office prostate biopsy. The finding of some insignificant prostate cancer was then license for misinformation, misrepresentation and falsehoods culminating in mismanagement and mistreatment. In fact, the risk of Gleason 6 (3+3) treatment harm is greater than the risk of the untreated insignificant prostate cancer. Dr Vorstman added, "Particularly disturbing is the gross overtreatment of most of these Gleason 6 (3+3) prostate cancers with the toxic, irreversible radical surgery/robotic prostatectomy for which there is no evidence based medicine support. This unproven, emasculating radical surgery/robotic prostatectomy for insignificant Gleason 6 (3+3) cancers represents "modern day" human experimentation. "At 20 years, these patients, or "sufferers" are survivors of their treatment, not survivors of their insignificant cancer." Furthermore said Dr Vorstman, "The gross overdiagnosis and overtreatment of this non aggressive prostate cancer and the insignificant number of lives saved by the crippling surgical treatment have been underscored by the embarrassing USPSTF report on prostate cancer screening as well as the flurry of class action lawsuits against the robot equipment makers. In response to these concerns there have been some moves by urologists to readdress prostate cancer screening guidelines and to tighten the indications for the use of the highly unreliable PSA blood test (the AUA now suggesting greatest evidence for "benefit" from routine screening was for men ages 55 to 69 only) as well as address the burning issue of prostate cancer overdiagnosis. Regrettably though, concerns regarding the pervasive overtreatment of insignificant Gleason 6 (3+3) prostate cancer with the irreversible, unproven, high-risk robotic prostatectomy are not being addressed. Dr Vorstman's passion is the empowerment of men and their wives/partners about localized prostate cancer, management options and health choices. He is a dedicated patient advocate and an outspoken critic of overdiagnosis and overtreatment of the favorable-risk Gleason 6 (3+3) prostate cancer. His powerful messages and insights about prostate cancer reach many people through his website and blog, www.urologyweb.com To review Dr Vorstman's extensive writings on localized prostate cancer management go to http://www.urologyweb.com/exclusive-medical-reports/or, contact Dr Bert Vorstman at 877 783 4438 or, bvorstmanmd@gmail.com Media Contact: Dr. Bert Vorstman, UrologyWeb, 954-752-3166, bvorstmanmd@gmail.com SOURCE Urologyweb.com RELATED LINKS http://www.urologyweb.com